Drugs /

sgn-cd228a

Back to Drugs List

Overview

NCI Definition [1]:
An antibody-drug conjugate (ADC) composed of a humanized antibody targeting the cell surface antigen cluster of differentiation (CD228; melanotransferrin; MFI2; MELTF) that is conjugated, via a beta-glucuronidase-cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Following administration, the antibody moiety of anti-CD228/MMAE ADC SGN-CD228A targets and binds to CD228 on the surface of tumor cells. Following internalization of SGN-CD228A and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CD228-expressing tumor cells. CD228, a cell-surfaced, glycosylphosphatidylinoitol (GPI)-anchored glycoprotein, belongs to the transferrin family of iron-binding proteins.

Clinical Trials

View Clinical Trials for sgn-cd228a

Sgn-cd228a has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating sgn-cd228a, 1 is phase 1 (1 open).

EGFR A763_Y764insFQEA, EGFR Codon 719 Missense, and EGFR Exon 19 Deletion are the most frequent biomarker inclusion criteria for sgn-cd228a clinical trials.

Breast carcinoma, colorectal carcinoma, and cutaneous melanoma are the most common diseases being investigated in sgn-cd228a clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Sgn-Cd228a
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating sgn-cd228a and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-cd228 antibody-drug conjugate sgn-cd228a, anti-cd228-mmae adc sgn-cd228a, anti-cd228/mmae adc sgn-cd228a, anti-cd228/mmae antibody-drug conjugate sgn-cd228a, anti-melanotransferrin adc sgn-cd228a, sgn cd228a, sgncd228a
Drug Target(s) [2]:
MFI2
NCIT ID [1]:
C168772

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.